Dose Escalation Study of Intravitreal 4D-110 in Patients With Choroideremia

Running, not enrolling · Phase 1

Conditions studied: Choroideremia

In brief

This study will evaluate safety, tolerability, and preliminary efficacy of a single intravitreal (IVT) injection of a recombinant adeno-associated virus (AAV) gene therapy, 4D-110, in male patients with genetically-confirmed Choroideremia (CHM).

Key facts

Study ID

NCT04483440

Run by

4D Molecular Therapeutics

People needed

13

Starts

2020-06-02

Expected to finish

2027-08-31

Last updated by the study team

2025-05-22

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

Where it is running

• Retina Foundation of the Southwest — Dallas, Texas, United States
• Moran Eye Center, University of Utah — Salt Lake City, Utah, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.